Oligonucleotide CDMO Market Set for Rapid Growth and Trend by 2026-2031

BRUSSELS - June 22, 2026 - PRLog -- The demand for oligonucleotide-based therapies is accelerating as biotech and pharmaceutical companies advance innovations in antisense oligonucleotides (ASOs), siRNA, microRNA, aptamers, and other nucleic acid therapeutics.

This momentum is driving strong growth in the global Oligonucleotide CDMO market, which is projected to expand at an impressive 𝐂𝐀𝐆𝐑 𝐨𝐟 15% 𝐨𝐯𝐞𝐫 𝐭𝐡𝐞 𝐧𝐞𝐱𝐭 𝐟𝐢𝐯𝐞 𝐲𝐞𝐚𝐫𝐬.

Oligonucleotide CDMOs play a critical role by providing specialized development, scale-up, and manufacturing capabilities that help bring next-generation therapies from research to commercialization faster and more efficiently.

As precision medicine and RNA therapeutics continue to evolve, strategic partnerships between biotech innovators and CDMOs will remain essential for accelerating innovation, ensuring quality, and meeting growing global demand.

𝐊𝐞𝐲 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐒𝐡𝐚𝐩𝐢𝐧𝐠 𝐭𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭
Bachem Holding AG | Agilent Technologies | Lonza Group | Thermo Fisher Scientific | WuXi AppTec | ST Pharm Co., Ltd. | Eurofins Scientific | PolyPeptide Group | Ajinomoto Bio-Pharma Services | Aurigene Pharmaceutical Services Ltd | Kaneka Eurogentec S.A

𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗣𝗗𝗙: https://meditechinsights.com/oligonucleotide-cdmo-market/request-sample/